Encouraging gene therapy data give uniQure an injection of confidence as it preps PhIII showdown with Spark
Gene therapy company uniQure started the week in style with the news that it’s dosed the first patient in its Phase III trial — a crucial …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
